|
Quotes & Info
|
| PGNX > SEC Filings for PGNX > Form 8-K on 7-May-2009 | All Recent SEC Filings |
7-May-2009
Other Events, Financial Statements and Exhibits
On May 7, 2009, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced results from the one-month, double-blind portion of a phase 3 trial evaluating RELISTOR® (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation in patients with chronic, non-cancer pain.
A copy of the press release is attached hereto as Exhibit 99.1 and the information contained therein is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
(d) Exhibits
Exhibit No. Description
99.1 Press Release dated May 7, 2009.
|
|